Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Dimopoulos, M. A.; Leleu, X.; Palumbo, A.; Moreau, P.; Delforge, M.; Cavo, M.; Ludwig, H.; Morgan, G. J.; Davies, F. E.; Sonneveld, P.; Schey, S. A.; Zweegman, S.; Hansson, M.; Weisel, K.; Mateos, M. V.; Facon, T.; Miguel, J. F. S.

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2014-10-30T17:04:05Z
dc.date.available	2014-10-30T17:04:05Z
dc.date.issued	2014
dc.identifier.issn	0887-6924
dc.identifier.uri	http://hdl.handle.net/10900/57289
dc.language.iso	en	de_DE
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/leu.2014.60	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20141022002833_00330	de_DE
utue.publikation.seiten	1573-1585	de_DE
utue.personen.roh	Dimopoulos, M. A.
utue.personen.roh	Leleu, X.
utue.personen.roh	Palumbo, A.
utue.personen.roh	Moreau, P.
utue.personen.roh	Delforge, M.
utue.personen.roh	Cavo, M.
utue.personen.roh	Ludwig, H.
utue.personen.roh	Morgan, G. J.
utue.personen.roh	Davies, F. E.
utue.personen.roh	Sonneveld, P.
utue.personen.roh	Schey, S. A.
utue.personen.roh	Zweegman, S.
utue.personen.roh	Hansson, M.
utue.personen.roh	Weisel, K.
utue.personen.roh	Mateos, M. V.
utue.personen.roh	Facon, T.
utue.personen.roh	Miguel, J. F. S.
dcterms.isPartOf.ZSTitelID	Leukemia	de_DE
dcterms.isPartOf.ZS-Issue	8	de_DE
dcterms.isPartOf.ZS-Volume	28	de_DE